Stocks To Buy Now

Blog


DGE 8th Decentralized & Hybrid Clinical Trials Conference to be Held in Philadelphia, PA

Executives and professionals of the biopharma and medical device realm are invited to attend the 8th Decentralized & Hybrid Clinical Trial conference organized by DGE, May 15-16, 2024, in Philadelphia, PA. The event focuses on optimizing the technical processes, regulatory compliance, and design adaptability of remote clinical trials.

The conference is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. The global event company caters to the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries.

During COVID-19, remote and decentralized clinical trials (DCTs) came into practice. Since then, the application of decentralized methods for clinical trials has grown phenomenally. Thus, clinical trial teams have to be prepared and equipped to incorporate the relevant technologies for decentralized methods. This conference explores insights into challenges and offers solutions for selecting the right technologies for patients and sites, understanding FDA guidelines, overcoming logistical hurdles, and much more.

Experts conducting speaker sessions will also talk about how the power of AI can be harnessed for various clinical trial processes such as attaining patient data in DCTs, and also when solving issues of tech affordability, bias, and inconsistent data management. Additional topics include the importance of home sampling for decentralized trials, and uses of eConsent.

The event is meticulously curated to address challenges and offer solutions to the clinical trial industry. DGE offers a phenomenal networking platform to meet, learn, and connect with the right professionals and influencers. Connect with industry leaders, showcase unique ideas and presentations, and get the latest updates to stay ahead of the competition.

To know more, please visit https://ibn.fm/r97GX.

From Our Blog

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

May 9, 2025

A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid manufacturers […]

Rotate your device 90° to view site.